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Introduction 
 
     According to the 2014 Centers for 
Disease Control (CDC) 9.3% of the United 
States Population have diabetes (National 
diabetes statistics report, “2014, p.1).  One 
of the complications of diabetes is 
gastroparesis.  Gastroparesis is “a delay in 
the emptying of ingested food in the 
absence of mechanical obstruction of the 
stomach or duodenum ‘’ (Koch & Calles-
Escandon, 2015, p. 40).  Mortality in the 
diabetic patient with gastroparesis is higher 
than the diabetic patient without 
gastroparesis (Koch & Calles-Escandon, 
2015).  Patients with either type 1 diabetes 
(T1DM) or type 2 diabetes (T2DM) may 
experience he clinical symptoms of early 
satiety, prolonged fullness, nausea, and 
vomiting, and have difficulties with 
management of blood glucose levels, 
nutritional issues, and other drug 
absorption issues (Koch & Calles-Escandon, 
2015).  Health care providers may see 
patients in a variety of settings, with and 
without known diagnosis of gastroparesis 
and must be aware of the symptoms, the 
potential diagnosis, the appropriate 
testing, and the options for treatment.  
Advances in the treatment of gastroparesis 
surround the increased understanding of 
the pathophysiology behind gastroparesis. 
 
 
Signs & symptoms 
 
• nausea 
• early satiety 
• bloating 
• abdominal or epigastric pain 
• impaired glycemic control 
• malnutrition 
• poor drug absorption 
• poor quality of life 
• frequent hospitalizations  
        (Shin & Camilleri, 2013) 
 
 
 
 
Pathophysiology  
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       There are several alterations suspected in gastroparesis. 
• The most common abnormality is loss or depletion of ICCs . ICCs  
regulate contractility and impaired ICCs results in gastric 
dysrhythmias (Farrugia, 2015). 
•  Damage to the vagus nerve innervation to the stomach, may lead to 
motor abnormalities and abnormal relaxation of the pylorus  
(Farrugia ,2015). 
•  Evidence has shown smooth muscle degeneration and end stage 
evidence may include fibrosis with eosinophilic inclusion bodies 
(Farrugia, 2015). 
•  Loss of neurotransmitters, such as neuronal nitric oxide synthase 
(nNOS) have been seen and are thought to be reversible (Farrugia, 
2015).  Nitregic neuron loss and ICC loss is thought to account of the 
poor fundic relaxation and decreased gastric capacity that is seen in 
gastroparesis (Koch & Calles-Escandon, 2015). 
• Fibroblast-like cells (FLCs), similar to ICCs are involved in 
neurotransmission, and may be decreased  in gastroparesis 
(Farrugia, 2015).  
•  Alterations in the balance of pro-inflammatory M1 macrophages 
and anti-inflammatory M2 macrophages of the stomach wall muscle  
are suspected to become disrupted in gastroparesis (Farrugia, 2015).  
M1 macrophages are associated with the development of delayed 
gastric emptying (Farrugia, 2015).   
The normal activity in gastric motility involves three areas of action. 
• The fundus, which relaxes with a volume of food ingested and 
requires an intact vagus nerve and enteric neurons (Koch & 
Calles-Escandon, 2015) 
• The corpus and antrum, which produce recurrent waves at a 
frequency of 3 cycles per minute, turning digested food solids 
into finer material called chyme.  These peristaltic waves are 
controlled by gastric pacemaker cells call Interstitial cells of 
cajal (ICCs) (Koch & Calles-Escandon, 2015). 
• The emptying of chyme through the pylorus into the 
duodenum.  The pylorus regulates the volume and particle 
size of chyme and is affected by catecholamine and peptide 
releases (Koch & Calles-Escandon, 2015).  
 
  Diabetic patients often experience 
gastroparesis.  A cure for gastroparesis is not 
present.  Research and better understanding of the 
pathophysiology of gastric motility and function is 
needed to further advance the treatment of 
gastroparesis and its symptoms.  Until then, 
knowledge of the prevalence of gastroparesis in 
diabetics, symptom awareness, testing, and 
appropriate choosing of available medical therapies 
is important.  Support of the patient in nutrition and 
glycemic management is needed, as well as support 
of the patient’s emotional well being. 
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Conclusion 
Significance of Pathophysiology on 
Gastroparesis 
 
• Understanding the various potential alterations that lead to gastroparesis can affect the 
treatment or management of symptoms and mode of testing.  
• The gold standard test used for evaluation of gastric emptying is the gastric emptying 
study (GES), although associations are weak between abnormal results and patient 
symptoms due to various pathophysiology mechanisms (Shin & Camilleri, 2013). 
• Alternative methods of testing exist  (Shin & Camilleri, 2013).    
• Assessment of symptoms and other factors, such as age, sex, comorbidities, patient 
preference, and test availability should contribute to the decision of mode of testing 
(Shin & Camilleri, 2013). 
• Treatments are palliative and empiric in focus and not curative (Pasricha, 2015).   
• Common treatments aimed at increasing gastric emptying (Pasricha, 2015).  
•  Nutritional support, fluid and electrolyte restoration, glycemic control,  (Acosta & 
Camilleri, 2015) .  
• Six or more meals or snacks a day are needed to meet nutritional needs and include 
restricted fat and fiber intake: tolerance is improved with liquids or ground foods (Rees 
Parish, 2015).   
• Prokinetic medication help gastric emptying by “restoring the synchronicity between 
delivery of food and hormone and peptide release, but it does not target the underlying 
defects” (Farrugia, 2015, p. 6).   
• Metoclopramide, a dopamine 2 receptor agonist, is the only approved prokinetic 
medication in the United States; use is limited to less than 13 weeks of treatment 
(Acosta & Camilleri, 2015).    
• Domperidone is another dopamine 2 agonist, but use is considered investigational 
(Acosta & Camilleri, 2015).   
•  Antiemetic medications are often utilized for control of nausea,  but one study suggests 
that antiemetics show modest benefit in comparison to non- use (Hasler, 2015).   
• Opiate analgesia are often used but use could exacerbate nausea and vomiting and also 
slow gastric emptying (Hasler, 2015).   
• Hyperglycemia  treatment with insulin, may improve and normalize ICCs (Koch & Calles-
Escandon, 2015).    
•  Gastric pacemakers provide gastric electrical stimulation aimed at controlling nausea 
and improving vagal function when other therapies failed ; more understanding of 
gastric mapping is needed (Sarosiek et al., 2015).     
• A jejunostomy tube may be needed for patients experiencing gastroparesis in order to 
maintain hydration, nutrition, and glycemic control.   
• Newer agents are being studied and developed by targeting different pathways and 
include serotonin receptor agonists, ghrelin agonists (Acosta & Camilleri, 2015). 
Implications for Nursing 
Care 
     Having an understanding of the diagnosis of 
gastroparesis, symptom recognition, and understanding 
of the behind it, is important for nurses in a variety of 
roles.  Diabetic patients are often afflicted with 
gastroparesis.  Gastroparesis affects glycemic control 
and lack of glycemic control can lead to gastroparesis 
(Koch & Calles-Escandon, 2015).  Nurses can have   
pivotal role in diabetic education affecting glycemic 
control.  Dietary education in tandem with dietary 
professionals, can also provide symptomatic relief from 
those suffering from gastroparesis.  Knowledge of 
gastroparesis and medication therapy can also benefit 
patients through nurse request for appropriate 
medication, and patient education of those drugs.    
Advance practice nurse knowledge of gastroparesis, can 
lead to improvement is patient assessments, testing, 
symptom management, awareness of potential 
electrolyte imbalance, and patient nutrition and 
diabetes management.  Since the symptoms of 
gastroparesis lead to frequent medical visits and 
hospitalization, sensitivity to patient quality of life and 
screening for symptoms of depression may be 
important. 
 
 
  
 
  
  
  
  
  
  
  
Normal gastric neuromuscular function (Koch & 
Calles-Escandon, 2015)  
Neuromuscular function in gastroparesis  (Koch & Calles-Escandon, 2015) 
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